Lv4
450 积分 2022-08-12 加入
Lysosomotropic agents including azithromycin, chloroquine and hydroxychloroquine activate the integrated stress response
9小时前
待确认
Targeting Cancer Lysosomes with Good Old Cationic Amphiphilic Drugs
9小时前
已完结
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
1个月前
已完结
Real-World Genomic Profile of EGFR Second-Site Mutations and Other Osimertinib Resistance Mechanisms and Clinical Landscape of NSCLC Post-Osimertinib
1个月前
已完结
Targeting BRAF Activation as Acquired Resistance Mechanism to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small-Cell Lung Cancer
1个月前
已完结
Development and Validation of Targeted Gene Sequencing Panel Based Companion Diagnostic for Korean Patients with Solid Tumors
1个月前
已关闭
Structure-based classification predicts drug response in EGFR-mutant NSCLC
1个月前
已完结
Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer
2个月前
已完结
RE: Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer
2个月前
已完结
A clinical review on third and fourth generation EGFR tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
4个月前
已完结
皖公网安备34019202002308
